Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Appointed CFO
Quarterly results
Acq. announced
Director departure
CC transcript
MGI PHARMA INC (MOGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/17/2007 8-K Quarterly results
Docs: "MGI PHARMA Reports Third Quarter 2007 Financial Results"
07/18/2007 8-K Quarterly results
Docs: "MGI PHARMA Reports Second Quarter 2007 Financial Results"
04/18/2007 8-K Quarterly results
Docs: "MGI PHARMA Reports First Quarter 2007 Financial Results"
02/07/2007 8-K Quarterly results
Docs: "MGI PHARMA Reports Fourth Quarter and Full Year 2006 Financial Results"
10/18/2006 8-K Quarterly results
Docs: "MGI PHARMA Reports Third Quarter 2006 Financial Results"
07/19/2006 8-K Quarterly results
Docs: "MGI PHARMA REPORTS SECOND QUARTER 2006 FINANCIAL RESULTS"
04/19/2006 8-K Quarterly results
Docs: "MGI PHARMA REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS —First Quarter Highlighted by Execution of Pipeline Initiatives"
02/08/2006 8-K Quarterly results
Docs: "PRESS RELEASE ANNOUNCING FINANCIAL RESULTS"
10/19/2005 8-K Quarterly results
Docs: "MGI PHARMA REPORTS THIRD QUARTER FINANCIAL RESULTS —Aloxi Injection Sales Total $63.6 Million, A 34% Increase Over Prior Year— —Dacogen Approvable Letter Update Provided— —Aquavan Injection Phase 2 Dosing Study Enrollment Complete"
07/13/2005 8-K Quarterly results
Docs: "MGI PHARMA REPORTS SECOND QUARTER RESULTS"
04/13/2005 8-K Quarterly results
Docs: "MGI PHARMA REPORTS FIRST QUARTER RESULTS —135% Increase In Total Revenue Over Prior Year— —Aloxi Injection Achieves #1 Share Position In Injectable CINV Market— —Q1 2005 Aloxi Sales Increase 207% From Q1 2004, Total $57.2 Million— —Saforis ™ New Drug Application Timeline Accelerated— —SPA Completed for Aloxi Injection in PONV and Aloxi Oral Formulation— —Dacogen ™ Registration Program in Acute Myeloid Leukemia Initiated— MINNEAPOLIS, April 13, 2005 — MGI PHARMA, INC. , an oncology-focused biopharmaceutical company, today announced that total revenue for the first quarter of 2005 was $63.2 million, including Aloxi injection sales of $57.2 million. GAAP net income for the first quarter of 2005 was $11.6 million, or $0.15 per diluted share. At March 31, 2005, MGI PHARMA's unrestricted cash an..."
10/13/2004 8-K Quarterly results
Docs: "MGI PHARMA REPORTS THIRD QUARTER FINANCIAL RESULTS —Sales of Aloxi injection total $47.6 million for the third quarter— —Aloxi injection sales guidance increased for FY2004— —Dacogen ™ , ZYCOS, and Aesgen transactions completed"
07/14/2004 8-K Quarterly results
Docs: "MGI PHARMA REPORTS SECOND QUARTER FINANCIAL RESULTS"
04/14/2004 8-K Quarterly results
Docs: "MGI PHARMA REPORTS FIRST QUARTER 2004 FINANCIAL RESULTS First Quarter Aloxi ™ Injection Sales Total $18.6 Million Aloxi ™ Injection Guidance Revised Upwards to $115 to $130 Million for 2004"
10/15/2003 8-K Quarterly results
Docs: "MGI PHARMA REPORTS 2003 THIRD QUARTER FINANCIAL RESULTS"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy